Filing Details
- Accession Number:
- 0001104659-21-135790
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-08 18:00:37
- Reporting Period:
- 2021-11-04
- Accepted Time:
- 2021-11-08 18:00:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1533998 | Dariohealth Corp. | DRIO | Surgical & Medical Instruments & Apparatus (3841) | 452973162 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1710439 | Dror Bacher | 142 W 57Th St., 8Th Fl. New York NY 10019 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-11-04 | 200 | $19.08 | 171,930 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-11-05 | 200 | $19.06 | 171,730 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 to $19.10, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.09, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).